While molecular targeted therapy is currently the primarytreatment for BC, it is usually ineffective for TNBC due to the lackof ER, PR, and HER2 expression,3 highlightingan urgent clinical need to identify new therapeutic targets and developeffective drugs. The gene discussed is ERBB2; the disease is breast cancer.